PPARD and cardiac hypertrophy: Indeed, rather than the physiological cardiac hypertrophy observed with the PPARβ/δ agonist, endothelial-specific PPARβ/δ overexpressing mice develop a pathological cardiac hypertrophy that was suggested to be a consequence of an altered balance of PPARβ/δ activity between the vascular and muscular compartments8,17.